A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 2, 2013, Pages 471-482

  Terranova, Nadia ^a   Germani, Massimiliano ^b   Del Bene, Francesca ^b   Magni, Paolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Accelera Srl   (Italy)

Author keywords

Drug combination therapy; Drug interaction; Pharmacokinetic pharmacodynamic model; Tumor growth inhibition model; Xenograft mice

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR VOLUME;

ALGORITHMS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; KINETICS; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880922548     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2208-8     Document Type: Article

References (29)

1. Asawari: SimBiology model for PK/PD of anticancer drugs. Matlab Central, http://www.mathworks.com/matlabcentral/fileexchange/32929-simbiology-model-for- pkpd-of-anticancer-drugs(2011)
2. Berenbaum M (1989) What is synergy? Parmacol Rev 41:93-141 (Pubitemid 20019599)
3. Bonate PL (2011) Modeling tumor growth in oncology. In: Bonate PL, Howard D (eds) Pharmacokinetics in drug development. American Association of Pharmaceutical Scientists, Sringer, US, pp 1-19. ISBN: 978-1-4419-7936-0
4. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multilple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
5. De Vita V (1984) Principles of cancer management: chemotherapy. In: De Vita V, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott-Raven, Philadelphia
6. Della Pasqua OE (2011) PKPD and disease modeling: concepts and application to oncology. In: Kimko H, Peck C (eds) Clinical trial simulations, AAPS advances in the pharmaceutical sciences, vol 1, chap 13. Springer, New York, pp 277-306
7. Drewinko B, Loo T, Brown B, Gottlieb J, Freireich E (1976) Combination chemotherapy in vitro with Adriamycin. Observations of additive, antagonistic and synergistic effects when used in two-drug combination on cultured human lymphoma cells. Cancer Biochem Biophys 1:187-195
8. Earp J, Krzyzanski W, Chakraborty A, Zamacona MK, Jusko W (2005) Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn 31:345-380
9. Germani M, Del Bene F, Rocchetti M, Van Der Graaf P (2013) A4S: a user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation. Comp Meth Prog 110:203-214
10. Goteti K, Garner CE, Utley L, Dai J, Ashwell S, Moustakas DT, Gonen M, Schwartz GK, Kern SE, Zabludoff S, Brassil PJ (2010) Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. Cancer Chemother Pharmacol 66:245-254
11. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a responde surface perspective. Pharmacol Rev 47(2):332-382
12. Greco WR, Park HS, Rustum YM (1990) An application of a new approach for the quantitation of drug synergism to the combination of cis- diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res 50:5318-5327 (Pubitemid 20302982)
13. James C, Breda M, Frigerio E, Long J, Munesada K (2002) Fast turnaround bioanalysis in discovery and early clinical development. Chromatographia 55(Suppl):S41-S43
14. Koch G, Walz A, Lahu G, Shoropp J (2009) Modeling of tumor growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn 36:179-197
15. Liu M, Hicklin D (2011) Human tumor xenograft efficacy models. In: Teicher B (ed) Tumor models in cancer research, cancer drug discovery and development. Springer, New York
16. Lopez AM, Pegram MD, Slamont DJ, Landaw EM (1999) A model-based approach for assessing in vivo combination therapy interactions. PNAS 96:13,023-13,028
17. Magni P, Germani M, De Nicolao G, Bianchini G, Simeoni M, Poggesi I, Rocchetti M (2008) A minimal model of tumor growth inhibition. IEEE Trans Biomed Eng 55(12):2683-2690
18. Magni P, Simeoni M, Poggesi I, Rocchetti M, De Nicolao G (2006) A mathematical model to study the effects of drugs administration on tumor growth dynamics. Math Biosci 200(2):127-151
19. Magni P, Terranova N, Del Bene F, Germani M, De Nicolao G (2012) A minimal model of tumor growth inhibition in combination regimens under the hypothesis of no interaction between drugs. IEEE Trans Biomed Eng 59:2161-2170
20. Rocchetti M, Del Bene F, Germani M, Fiorentini F, Poggessi I, Pesenti E, Magni P, De Nicolao G (2009) Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach. Eur J Cancer 45:3336-3346
21. Rocchetti M, Poggesi I, Germani M, Fiorentini F, Pellizzoni C, Zugnoni PEEP, Simeoni M, De Nicolao G (2005) A pharmacokinetic-pharmacodynamic model for predicting tumour growth inhibition in mice: a useful tool in oncology drug development. Basic Clin Pharmacol Toxicol 96:265-268 (Pubitemid 40388012)
22. Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I (2007) Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer 43:1862-1868 (Pubitemid 47243652)
23. Schwartz G (2005) Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol 23:4499-4508 (Pubitemid 46196579)
24. Shah M, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen D, Schwartz G (2005) A phase I clinical trial of the sequential combination of Irinotecan followed by Flavopiridol. Clin Cancer Res 11:3836-3845 (Pubitemid 40685604)
25. Simeoni M, De Nicolao G, Magni P, Rocchetti M, Poggesi I (2012) Modeling of human tumor xenografts and dose rationale in oncology. Drug Discovery Today: Technologies (2012 available on line). doi: 10.1016/j.ddtec.2012.07.004
26. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094-1101 (Pubitemid 38176915)
27. Terranova N, Magni P (2012) TGI-Simulator: a visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug. Comput Methods Programs Biomed 105(2):162-174
28. Zabludoff SD, Deng C, Grondine M, Sheehy AM, Ashwell S, Caleb B, Green S, Haye H, Horn C, Janetka J, Liu D, Mouche E, Ready S, Rosenthal JL, Queva C, Schwarts G, Taylor K, Tse A, Walker G, White A (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoit abrogation and potentiales DNA-targeted therapies. Mol Cancer Ther 7:2955-2966
29. Zandvliet A, Siegel-Lakhai W, Beijnen J, Copalu W, Etienne-Grimaldi M, Milano G, Schellens J, Huitema A (2008) PK/PD model of Indisulam and Capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 83:829-839 (Pubitemid 351704912)